7,504 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Aigen Investment Management LP

Aigen Investment Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,504 shares of the company’s stock, valued at approximately $415,000.

A number of other large investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company’s stock valued at $5,644,000 after purchasing an additional 498 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock valued at $449,000 after purchasing an additional 789 shares in the last quarter. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at about $53,000. Rhumbline Advisers raised its position in Tarsus Pharmaceuticals by 2.1% during the fourth quarter. Rhumbline Advisers now owns 49,534 shares of the company’s stock valued at $2,743,000 after purchasing an additional 1,019 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Tarsus Pharmaceuticals by 9.3% during the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after purchasing an additional 1,033 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 6.7 %

NASDAQ TARS opened at $46.47 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $1.78 billion, a PE ratio of -12.20 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The business’s 50-day moving average is $50.14 and its 200 day moving average is $43.61.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Jefferies Financial Group raised their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday. Barclays decreased their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Guggenheim reiterated a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.